Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer

EGFR 在非小细胞肺癌 DNA 修复和放射反应中的作用

基本信息

  • 批准号:
    8664066
  • 负责人:
  • 金额:
    $ 19.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-01 至 2015-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Radiotherapy, either alone, or in combination with chemotherapy, is frequently used in the treatment of patients with non-small cell lung carcinoma. However, tumor responses to ionizing radiation vary considerably and radiotherapy is not always effective in NSCLC patients. The epidermal growth factor receptor is an important determinant of radioresponse, whose elevated expression and activity frequently correlates with radioresistance in NSCLC tumors. We recently identified a subset of patient- derived NSCLC cell lines that exhibit marked sensitivity to radiation. A consistent feature among these NSCLCs is that they all harbor somatic, activating mutations in the tyrosine kinase domain (TKD) of the EGFR, that have also been linked to tumor sensitivity to small molecule tyrosine kinase inhibitors, gefitinib and erlotinib. We have assembled multiple lines of evidence that support a potential mechanism underlying mutant EGFR-associated radiosensitivity. The evidence reveals that, unlike the wild type EGFR, receptors with activating mutations in the TKD are not only defective in radiation- induced translocation to the nucleus but also fail to bind the catalytic and regulatory subunits of the DNA-dependent protein kinase (DNA-PK). Consequently, NSCLCs with TKD-mutated EGFR exhibit significant delays in the repair of DNA double strand break repair and poor clonogenic survival in response to radiation. A crucial finding is that ectopic expression of TKD-mutated forms of EGFR can radiosensitize different cell lines with diverse genetic backgrounds, including radioprotective mutations in KRAS and p53. Our study has identified a subset of naturally occurring EGFR mutations that abrogate a critical radioprotective function of EGFR. We will use these as tools to address three specific aims of our proposal: (1) To confirm that NSCLCs with mutations in the tyrosine kinase domain of EGFR are defective in repair of radiation-induced DNA damage (2) To test the hypothesis that mutations in the tyrosine kinase domain of EGFR block radiation-induced nuclear translocation of EGFR and compromise DSB repair and clonogenic survival (3) To test the hypothesis that mutations in the tyrosine kinase domain of EGFR prevent radiation-induced EGFR-DNA-PK interactions and compromise DSB repair and clonogenic survival. The long term goal is to develop a molecular rationale for a radiotherapeutic strategy in NSCLC patients that simulates the radiosensitizing effects of TKD- mutated EGFR. Public Health Relevance: Nearly 75% of all lung cancers manifest as non-small lung carcinoma. The median five-year survival rate for patients diagnosed with non-small lung cancer (NSCLC) is estimated at barely 14%. Radiotherapy is the first and sometimes only line of treatment for patients with NSCLCs. However, tumor resistance to ionizing radiation presents a major challenge to radiotherapeutic control of NSCLCs. Efficient DNA repair pathways in radioresistant tumors are frequently augmented by molecular determinants of radioresponse such as the epidermal growth factor receptor (EGFR). One of the critical radioprotective functions of EGFR involves radiation induced nuclear transport and interactions with key enzymes in DNA repair pathways. The immediate objective is to elucidate mechanisms underlying the radiosensitivity associated with a biologically distinct class of NSCLCs that harbor mutations in the tyrosine kinase domain (TKD) of EGFR. The long term goal is to develop a radiotherapeutic strategy that simulates the radiosensitizing effects of TKD-mutated EGFR in NSCLC patients.
描述(由申请人提供):放射疗法,无论是单独使用,还是与化疗联合使用,经常用于治疗非小细胞肺癌患者。然而,肿瘤对电离辐射的反应差异很大,放疗对 NSCLC 患者并不总是有效。 The epidermal growth factor receptor is an important determinant of radioresponse, whose elevated expression and activity frequently correlates with radioresistance in NSCLC tumors.我们最近鉴定了一个源自患者的 NSCLC 细胞系子集,它们对辐射表现出明显的敏感性。这些 NSCLC 的一个一致特征是,它们都在 EGFR 酪氨酸激酶结构域 (TKD) 中存在体细胞激活突变,这些突变也与肿瘤对小分子酪氨酸激酶抑制剂吉非替尼和厄洛替尼的敏感性有关。我们收集了多种证据,支持突变型 EGFR 相关放射敏感性的潜在机制。证据表明,与野生型 EGFR 不同,TKD 中具有激活突变的受体不仅在辐射诱导的细胞核易位方面存在缺陷,而且无法结合 DNA 依赖性蛋白激酶 (DNA-PK) 的催化和调节亚基。因此,具有 TKD 突变 EGFR 的 NSCLC 在 DNA 双链断裂修复方面表现出显着延迟,并且响应辐射的克隆存活率较差。 A crucial finding is that ectopic expression of TKD-mutated forms of EGFR can radiosensitize different cell lines with diverse genetic backgrounds, including radioprotective mutations in KRAS and p53.我们的研究已经确定了自然发生的 EGFR 突变的子集,这些突变消除了 EGFR 的关键放射防护功能。我们将使用这些作为工具来实现我们提案的三个具体目标:(1) 确认 EGFR 酪氨酸激酶结构域突变的 NSCLC 在修复辐射诱导的 DNA 损伤方面存在缺陷 (2) 检验 EGFR 酪氨酸激酶结构域突变阻断辐射诱导的 EGFR 核易位并损害 DSB 修复和克隆存活的假设 (3) 检验以下假设:EGFR 酪氨酸激酶结构域的突变可阻止辐射诱导的 EGFR-DNA-PK 相互作用并损害 DSB 修复和克隆存活。 The long term goal is to develop a molecular rationale for a radiotherapeutic strategy in NSCLC patients that simulates the radiosensitizing effects of TKD- mutated EGFR.公共健康相关性:所有肺癌中近 75% 表现为非小肺癌。诊断为非小细胞肺癌 (NSCLC) 的患者的中位五年生存率估计仅为 14%。放射治疗是非小细胞肺癌患者的首选治疗方法,有时也是唯一的治疗方法。然而,肿瘤对电离辐射的抵抗对非小细胞肺癌的放射治疗控制提出了重大挑战。放射抗性肿瘤中的有效 DNA 修复途径经常被放射反应的分子决定因素(例如表皮生长因子受体 (EGFR))增强。 EGFR 的关键辐射防护功能之一涉及辐射诱导的核运输以及与 DNA 修复途径中关键酶的相互作用。 The immediate objective is to elucidate mechanisms underlying the radiosensitivity associated with a biologically distinct class of NSCLCs that harbor mutations in the tyrosine kinase domain (TKD) of EGFR.长期目标是开发一种放射治疗策略,模拟 NSCLC 患者中 TKD 突变 EGFR 的放射增敏作用。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells.
  • DOI:
    10.1038/srep11305
  • 发表时间:
    2015-06-11
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Amornwichet N;Oike T;Shibata A;Nirodi CS;Ogiwara H;Makino H;Kimura Y;Hirota Y;Isono M;Yoshida Y;Ohno T;Kohno T;Nakano T
  • 通讯作者:
    Nakano T
Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization.
  • DOI:
    10.1016/j.semradonc.2010.05.002
  • 发表时间:
    2010-10
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Mukherjee, Bipasha;Choy, Hak;Nirodi, Chaitanya;Burma, Sandeep
  • 通讯作者:
    Burma, Sandeep
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chaitanya Suresh Nirodi其他文献

Chaitanya Suresh Nirodi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chaitanya Suresh Nirodi', 18)}}的其他基金

Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer
EGFR 在非小细胞肺癌 DNA 修复和放射反应中的作用
  • 批准号:
    8076180
  • 财政年份:
    2008
  • 资助金额:
    $ 19.24万
  • 项目类别:
Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer
EGFR 在非小细胞肺癌 DNA 修复和放射反应中的作用
  • 批准号:
    7524320
  • 财政年份:
    2008
  • 资助金额:
    $ 19.24万
  • 项目类别:
Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer
EGFR 在非小细胞肺癌 DNA 修复和放射反应中的作用
  • 批准号:
    7644001
  • 财政年份:
    2008
  • 资助金额:
    $ 19.24万
  • 项目类别:
Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer
EGFR 在非小细胞肺癌 DNA 修复和放射反应中的作用
  • 批准号:
    7825271
  • 财政年份:
    2008
  • 资助金额:
    $ 19.24万
  • 项目类别:
Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer
EGFR 在非小细胞肺癌 DNA 修复和放射反应中的作用
  • 批准号:
    8265309
  • 财政年份:
    2008
  • 资助金额:
    $ 19.24万
  • 项目类别:

相似国自然基金

招募磷酸酶的光控DNA纳米嵌合体用于EGFR灭活及抗非小细胞肺癌耐药的研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    15.0 万元
  • 项目类别:
    省市级项目
EGFR-LncRNA ITGΒ4-AS-DNA 甲基化轴调控哮喘 气道上皮整合素β4 低表达机制研究
  • 批准号:
    2024JJ5054
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
DNA甲基化抑制ACAP3通过调控EGFR囊泡运输促进肺腺癌进程的机制及生物标志物研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0 万元
  • 项目类别:
    青年科学基金项目
靶向DNA-PK克服非小细胞肺癌三代EGFR-TKI获得性耐药的作用和机制研究
  • 批准号:
    82272672
  • 批准年份:
    2022
  • 资助金额:
    52 万元
  • 项目类别:
    面上项目
基于EGFR、HIF-1α和DNA-PKcs靶点组合研究黄芪改善肺癌放疗抵抗的物质基础及分子机制
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    33 万元
  • 项目类别:
    地区科学基金项目
铁离子介导携带miRNA自组装DNA纳米材料的构建及其靶向EGFR-C797S突变型非小细胞肺癌的作用与机制研究
  • 批准号:
    82002456
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
结合诱导DNA组装的核酸探针用于活细胞膜表面EGFR蛋白二聚化成像的研究
  • 批准号:
    21904054
  • 批准年份:
    2019
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
胞质DNA-STING-IFN通路调控非小细胞肺癌脑转移放疗联合EGFR-TKI治疗敏感性的机制研究
  • 批准号:
    81903121
  • 批准年份:
    2019
  • 资助金额:
    21.5 万元
  • 项目类别:
    青年科学基金项目
缺氧诱导胞核EGFR磷酸化NONO促进DNA修复在肿瘤放疗抵抗中的作用及机制
  • 批准号:
    81872188
  • 批准年份:
    2018
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目
DNA损伤修复在非小细胞肺癌EGFR-TKI获得性耐药的分子机制研究
  • 批准号:
    81802283
  • 批准年份:
    2018
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Mechanism for resistance EGFR blockade; Analysis using circulating tumor DNA and circulating tumor cell
EGFR阻断的耐药机制;
  • 批准号:
    17K10657
  • 财政年份:
    2017
  • 资助金额:
    $ 19.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Detection of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer using circulating tumor DNA
使用循环肿瘤DNA检测转移性结直肠癌患者抗EGFR单克隆抗体的获得性耐药
  • 批准号:
    17K10625
  • 财政年份:
    2017
  • 资助金额:
    $ 19.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study on anti-EGFR antibody-resistant conquest of high DNA methylation type colorectal cancer
抗EGFR抗体战胜高DNA甲基化型结直肠癌耐药的研究
  • 批准号:
    15H04307
  • 财政年份:
    2015
  • 资助金额:
    $ 19.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Acquired resistance mechanism to EGFR-TKI using circulating cell-free tumor DNA
利用循环游离肿瘤DNA对EGFR-TKI获得性耐药机制
  • 批准号:
    15K21526
  • 财政年份:
    2015
  • 资助金额:
    $ 19.24万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Interpretation for the mechanism of acquired resistance of EGFR blockade by using cell free DNA
利用游离DNA解读EGFR阻断获得性耐药机制
  • 批准号:
    26462030
  • 财政年份:
    2014
  • 资助金额:
    $ 19.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The potency of DNA repair suppression mediated by DNA-PKcs de-phosphorylation through blocking of EGFR nuclear translocation
DNA-PKcs 去磷酸化通过阻断 EGFR 核易位介导的 DNA 修复抑制效力
  • 批准号:
    26830075
  • 财政年份:
    2014
  • 资助金额:
    $ 19.24万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers
EGFR靶向放射免疫疗法联合化疗和DNA修复抑制:侵袭性癌症的临床应用发展
  • 批准号:
    FT130101417
  • 财政年份:
    2014
  • 资助金额:
    $ 19.24万
  • 项目类别:
    ARC Future Fellowships
EGFR inhibitor and DNA double strand breaks
EGFR 抑制剂和 DNA 双链断裂
  • 批准号:
    21791195
  • 财政年份:
    2009
  • 资助金额:
    $ 19.24万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Interaction of EGFR and DNA repair processes: Relevance for the radioresistance of solid tumors (B02)
EGFR 和 DNA 修复过程的相互作用:与实体瘤放射抗性的相关性 (B02)
  • 批准号:
    80954392
  • 财政年份:
    2008
  • 资助金额:
    $ 19.24万
  • 项目类别:
    Collaborative Research Centres
Role of EGFR in DNA Repair and Radiation Response in Non Small Cell Lung Cancer
EGFR 在非小细胞肺癌 DNA 修复和放射反应中的作用
  • 批准号:
    8076180
  • 财政年份:
    2008
  • 资助金额:
    $ 19.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了